1
|
Pagano S, Alfaiate D, Juillard C, Frias M, Magenta A, Martino F, Sciaqua A, Succurro E, Burger F, Brandt K, Andreozzi F, Mach F, Perticone M, Vuilleumier N. High antibody titers against apolipoprotein-A1 in NAFLD: A possible link between fatty liver disease and CVD? Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
2
|
Pagano S, Alfaiate D, Juillard C, Frias M, Magenta A, Martino F, Sciaqua A, Succurro E, Burger F, Brandt KJ, Andreozzi F, Mach F, Perticone M, Vuilleumier N. Autoantibodies directed against apolipoprotein A-1 as a potential contributor to non-alcoholic fatty liver disease. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in these patients. Although NAFLD pathophysiology is not fully understood alterations in fat metabolism seem to play a role. Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) are a novel cardiovascular risk factor to which have been recently attributed a metabolic role in addition to a well-established macrophage-mediated inflammatory effect and have a function as a disruptor of the cholesterol pathway.
Purpose
This study aims at evaluating a possible role of anti-apoA-1 IgG in NAFLD.
Methods
Serum from 137 NAFLD patients were tested for anti-apoA-1 IgG prevalence. In vitro, SREBP1, SREBP2 expressions were assessed in the human hepatic cell line HepaRG by western blot analysis and bodipy staining was used to evaluate the lipid droplet content. Mescoscale technology platform was used to measure TNF-α, IL-6 and IL-8 cytokines/chemokines in HepaRG supernatants. Oil Red O staining was used to detect lipid accumulation in liver sections from ApoE−/− mice.
Results
Elevated anti-apoA-1 IgG seropositivity was found in patients with NAFLD (46%). In vitro, anti-apoA-1 IgG and not control IgG induced lipid accumulation in hepatic cells (5.9 vs 2.5, P=0.0008) and this lipid overload was associated with a high SREBP1 but not SREBP2 expression. Furthermore, anti-apoA-1 IgG and not control antibodies caused a significant large increase of the proinflammatory cytokines IL-6 (680 vs. 163 pg/mL, P=0.03) and TNF-α (391 vs 266 pg/mL, P=0.04) as well as of the chemokine IL-8 (174.1 vs. 72.6 ng/mL, P=0.03) detected in the hepatic cell supernatants. In vivo, anti-apoA-1 IgG and not control IgG also induced higher lipid accumulation in the livers of ApoE−/− mice (1.23 vs 0.53, P=0.03).
Conclusion
Anti-apoA-1 IgG are frequent in NAFLD, cause a strong inflammatory response and promote lipid accumulation through SREBP1 activation in human hepatic cells. We hypothesize that anti-apoA1 IgG may be a potential contributor in the development of NAFLD.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): Geneva University Hospital
Collapse
Affiliation(s)
- S Pagano
- Geneva University Hospitals, Geneva, Switzerland
| | | | - C Juillard
- Geneva University Hospitals, Geneva, Switzerland
| | - M Frias
- Geneva University Hospitals, Geneva, Switzerland
| | - A Magenta
- National Research Council (CNR), Institute of Traslational Pharmacology (IFT), Rome, Italy
| | - F Martino
- Umberto I Polyclinic of Rome, Rome, Italy
| | - A Sciaqua
- Magna Graecia University of Catanzaro, Catanzaro, Italy
| | - E Succurro
- Magna Graecia University of Catanzaro, Catanzaro, Italy
| | - F Burger
- Geneva University Hospitals, Geneva, Switzerland
| | - K J Brandt
- Geneva University Hospitals, Geneva, Switzerland
| | - F Andreozzi
- Magna Graecia University of Catanzaro, Catanzaro, Italy
| | - F Mach
- Geneva University Hospitals, Geneva, Switzerland
| | - M Perticone
- Magna Graecia University of Catanzaro, Catanzaro, Italy
| | | |
Collapse
|
3
|
Pagano S, Alfaiate D, Juillard C, Frias M, Magenta A, Martino F, Sciacqua A, Succurro E, Burger F, Brandt K, Andreozzi F, Mach F, Perticone M, Vuilleumier N. Autoantibodies directed against apolipoprotein-A1 as a potential contributor to non-alcoholic fatty liver disease. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Meinzer U, See H, Bader-Meunier B, Juillard C, Duquesne A, Melki I, Faye A, Bourrat E. Clinical Characteristics of Acne Fulminans Associated With Chronic Nonbacterial Osteomyelitis in Pediatric Patients. J Rheumatol 2020; 47:1793-1799. [PMID: 32238518 DOI: 10.3899/jrheum.191232] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/20/2020] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Acne fulminans (AF) is a rare, explosive systemic form of acne. Chronic nonbacterial osteomyelitis (CNO) or chronic recurrent multifocal osteomyelitis (CRMO) is a primarily pediatric autoinflammatory disorder characterized by sterile osteolytic bone lesions. Concomitant occurrence of CNO/CRMO and AF is very rare, and little is known about the epidemiological and clinical particularities of this association. The aim of this retrospective observational study was to describe the characteristics of pediatric patients with CNO/CRMO associated to AF. METHODS Electronic mailing lists of French medical societies were used to call for patients with CNO/CRMO and AF. A search for published patients with CNO/CRMO and AF was performed by screening PubMed. RESULTS We identified 5 original patients and 10 patients from the literature. All patients were adolescent boys. Mean age at disease onset was 14.8 years. Nine of 15 patients had received isotretinoin before the sudden onset of AF. Osteoarticular symptoms appeared within < 1-3 months after the onset of AF. The mean numbers of clinical and radiological bone lesions were 3.6 and 5.6, respectively. The percentages of patients with involvement of vertebrae, pelvis, chest, and cranial were 40%, 40%, 33.3%, and 6.6%, respectively. Arthritis was observed in 69.2% of patients and sacroiliac arthritis in 46.2%. CONCLUSION CNO/CRMO associated to AF occurs predominantly in male adolescents and is characterized by frequent involvement of the axial skeleton and arthritis. Epidemiological and clinical features of these patients differ from general CNO/CRMO cohorts. Clinical management requires careful handling of isotretinoin doses.
Collapse
Affiliation(s)
- Ulrich Meinzer
- U. Meinzer, MD, PhD, Department of General Pediatrics, Pediatric Infectious Diseases and Pediatric Rheumatology, Hôpital Robert Debré, AP-HP, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-immune diseases (RAISE), and Université Paris Diderot-Sorbonne Paris-Cité, INSERM, UMR1149, and Biology and Genetics of Bacterial Cell Wall Unit, Institut Pasteur, Paris;
| | - Helene See
- H. See, MD, I. Melki, MD, PhD, Department of General Pediatrics, Pediatric Infectious Diseases and Pediatric Rheumatology, Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris AP-HP, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-immune diseases (RAISE), Paris
| | - Brigitte Bader-Meunier
- B. Bader-Meunier, MD, Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-immune diseases (RAISE), Paris
| | - Caroline Juillard
- C. Juillard, MD, Department of Dermatology, Hôpital Saint-Louis, Paris
| | - Agnes Duquesne
- A. Duquesne, MD, Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-immune diseases (RAISE), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon
| | - Isabelle Melki
- H. See, MD, I. Melki, MD, PhD, Department of General Pediatrics, Pediatric Infectious Diseases and Pediatric Rheumatology, Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris AP-HP, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-immune diseases (RAISE), Paris
| | - Albert Faye
- A. Faye, MD, PhD, Department of General Pediatrics, Pediatric Infectious Diseases and Pediatric Rheumatology, Hôpital Robert Debré, AP-HP, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Auto-immune diseases (RAISE), and Biology and Genetics of Bacterial Cell Wall Unit, Institut Pasteur, Paris
| | | | | |
Collapse
|
5
|
Ajiko MM, Davé D, Feldhaus I, Smith RN, Juillard C, Dicker RA. Patterns of surgical presentation at an African regional referral hospital: surveillance as a step towards improving access to care. Eur J Trauma Emerg Surg 2016; 43:265-272. [PMID: 26869519 DOI: 10.1007/s00068-016-0644-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Accepted: 02/01/2016] [Indexed: 11/28/2022]
Abstract
PURPOSE Surgical disease is being increasingly recognized as a significant health burden in Africa. Efforts have been made to describe surgical disease and capacity at the district hospital level. Little is known about patterns seen at regional hospitals supporting the district hospital network. METHODS This retrospective study was conducted at Uganda's Soroti Regional Referral Hospital, serving eight districts. Data were collected from July 2010 to March 2012 using operative and inpatient records as available. Univariate and bivariate analyses were performed to explore patterns of procedures performed and in-patient diagnoses. RESULTS There were 8511 procedures recorded in the operative log between July 2010 and June 2011, averaging 709 per month. Caesarian sections (41 %), dilation and evacuations (28 %), and laparotomies (19 %) were most frequent. Referrals to Soroti averaged 260 per month, while transfers out averaged 5 patients per month. Inpatient records documented 2949 surgically related diagnoses between July 2010 and May 2011. In patients >4 years old, 21 % of mortality was due to surgical disease, 29 % of which was trauma-related. Women comprised 80 % of violent injury. Common hospital record elements, such as demographic data, important clinical information, and operative notes were absent from these data sources. CONCLUSIONS The World Health Assembly recently recognized strengthening of first referral hospitals as a crucial element to achieving universal health coverage. Inconsistencies in recordkeeping despite the large volume of surgical disease suggest that sustainable surveillance systems and capacity building at the referral hospital level are potential building blocks to improving access to surgical care.
Collapse
Affiliation(s)
- M M Ajiko
- Soroti Regional Referral Hospital, Soroti-Lira Rd, Soroti, Uganda
| | - D Davé
- Department of Surgery, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, USA.,Department of Surgery, Center for Global Surgical Studies, University of California, San Francisco, 1001 Potrero Avenue, Ward 3A Box 0807, San Francisco, CA, USA
| | - I Feldhaus
- Department of Surgery, Center for Global Surgical Studies, University of California, San Francisco, 1001 Potrero Avenue, Ward 3A Box 0807, San Francisco, CA, USA
| | - R N Smith
- Department of Surgery, Penn Presbyterian Medical Center, University of Pennsylvania, 51 N 39th St., Philadelphia, PA, USA
| | - C Juillard
- Department of Surgery, Center for Global Surgical Studies, University of California, San Francisco, 1001 Potrero Avenue, Ward 3A Box 0807, San Francisco, CA, USA
| | - R A Dicker
- Department of Surgery, Center for Global Surgical Studies, University of California, San Francisco, 1001 Potrero Avenue, Ward 3A Box 0807, San Francisco, CA, USA.
| |
Collapse
|
6
|
Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, Lacour JP, D'Incan M, Dupin N, Sassolas B, Misery L, Chevrant-Breton J, Lebrun-Vignes B, Desseaux K, Valeyre D, Revuz J, Tazi A, Chosidow O, Dupuy A. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest 2014; 146:1046-1054. [PMID: 24945194 DOI: 10.1378/chest.14-0015] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports. The objective of this study was to evaluate the efficacy and safety of thalidomide in severe cutaneous sarcoidosis. METHODS This study consisted of a randomized, double-bind, parallel, placebo-controlled, investigator-masked, multicenter trial lasting 3 months and an open-label study from month 3 to month 6. Adults with a clinical and histologic diagnosis of cutaneous sarcoidosis were included in nine hospital centers in France. Patients were randomized 1:1 to oral thalidomide (100 mg once daily) or to a matching oral placebo for 3 months. In the course of an open-label follow-up from month 3 to month 6, all patients received thalidomide, 100 mg to 200 mg daily. The proportions of patients with a partial or complete cutaneous response at month 3, based on at least a 50% improvement in three target lesions scored for area and infiltration, were compared across randomization groups. RESULTS The intent-to-treat population included 39 patients. None of them had a complete cutaneous response. Four out of 20 patients in the thalidomide group (20%) vs four out of 19 patients in the placebo group (21%) had a partial cutaneous response at month 3 (difference in proportion of -1% [95% CI, -26% to +24%] for thalidomide vs placebo, P = 1.0). Eight patients with side effects were recorded in the thalidomide group vs three in the placebo group. We observed a large number of adverse event-related discontinuations in patients taking thalidomide in the first 3 months (four patients with thalidomide, zero with placebo) and in the 3 following months (five patients). CONCLUSIONS At a dose of 100 mg daily for 3 months, our results do not encourage thalidomide use in cutaneous sarcoidosis. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT0030552; URL: www.clinicaltrials.gov.
Collapse
Affiliation(s)
- Catherine Droitcourt
- Université de Rennes 1, Inserm CIC 1414, Rennes; Pharmacoepidemiology Unit, Inserm CIC 1414, Rennes
| | - Michel Rybojad
- The Department of Dermatology, Hôpital Saint-Louis, AP-HP, Paris
| | - Raphaël Porcher
- The Department of Biostatistics and Medical Informatics, Hôpital Saint-Louis, AP-HP, Paris; Université de Paris Diderot-Sorbonne Paris Cité, Paris; Inserm U717, Paris
| | | | | | - Pascal Joly
- 11 chaussée de la Muette, Paris; Clinique Dermatologique
| | - Jean-Philippe Lacour
- Inserm U905, Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen, Rouen; The Department of Dermatology, Hôpital Archet-2, CHU Nice, Nice
| | - Michel D'Incan
- Université de Nice, Sophia Antipolis, Nice; The Department of Dermatology, Clermont-Ferrand
| | - Nicolas Dupin
- The Department of Dermatology, Hôpital Cochin, AP-HP, Paris; Université René Descartes, Paris
| | | | - Laurent Misery
- CHU Estaing, and Université d'Auvergne Clermont-Ferrand; The Department of Dermatology, CHRU Brest, Brest
| | | | | | - Kristell Desseaux
- The Department of Biostatistics and Medical Informatics, Hôpital Saint-Louis, AP-HP, Paris; Université de Paris Diderot-Sorbonne Paris Cité, Paris; Inserm U717, Paris
| | | | | | - Abdellatif Tazi
- The Department of Pneumology, Hôpital Saint-Louis, AP-HP, Paris; Université de Paris Diderot-Sorbonne Paris Cité, Paris
| | - Olivier Chosidow
- UFR Medicine, Université de Brest, Brest; The Department of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil; UPEC Université de Paris Est-Créteil Val-de-Marne, Créteil; French satellite of the Cochrane Skin Group and Centre d'Investigation Clinique 006-Inserm, Créteil, France
| | - Alain Dupuy
- The Department of Dermatology, CHU Rennes; Université de Rennes 1, Inserm CIC 1414, Rennes; Pharmacoepidemiology Unit, Inserm CIC 1414, Rennes.
| |
Collapse
|
7
|
Guibal F, Resche-Rigon M, Juillard C, Cordoliani F, Moraillon I, Heudes AM, Ramel F, Baccard M, Bagot M, Lehucher-Ceyrac D. Isotrétinoïne et dépression : étude prospective contrôlée en pratique dermatologique de ville par mesure itérative du score Adolescent Depression Rating Scale (ADRS). Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Bounfour T, Bouaziz JD, Bézier M, Cordoliani F, Saussine A, Petit A, Juillard C, Bagot M, Rybojad M. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol 2013; 28:1150-7. [DOI: 10.1111/jdv.12223] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2013] [Revised: 05/15/2013] [Accepted: 07/02/2013] [Indexed: 11/30/2022]
Affiliation(s)
- T. Bounfour
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - J.-D. Bouaziz
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - M. Bézier
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - F. Cordoliani
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - A. Saussine
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - A. Petit
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - C. Juillard
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - M. Bagot
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| | - M. Rybojad
- Université Paris Diderot; Sorbonne Paris Cité; AP-HP; Service de Dermatologie; Hôpital Saint Louis; Paris France
| |
Collapse
|
9
|
Morizot G, Kendjo E, Mouri O, Thellier M, Pérignon A, Foulet F, Cordoliani F, Bourrat E, Laffitte E, Alcaraz I, Bodak N, Ravel C, Vray M, Grogl M, Mazier D, Caumes E, Lachaud L, Buffet PA, El Samad Y, Salle V, Gounod N, Dallot A, Belot G, Pelletier-Cunat S, Belon M, Verdon R, Rogeaux O, Grossetête G, Lesens O, Clabaut A, Maus E, Jouy L, Gener G, Perrin P, Roch N, Herve A, Le Duc D, Cuchet E, Maubon D, Hillion B, Menot E, Guillemot F, Beneton-Benhard N, Celerier P, Dupuis De Fonclare AL, Carre D, Bourgeois A, Marty P, Pomares C, Meunier L, Abergel H, Timsit F, Amoric JC, Busquet P, Karam S, Moisson YF, Mouly F, Ortoli JC, Consigny PH, Jouan M, Caby F, Datry A, Hochedez P, Rozembaum F, Dumortier C, Ancelle T, Dupin N, Paugam A, Ranque B, Bougnoux ME, Canestri A, Galezowsky MF, Hadj Rabia S, Hamel D, Schneider P, Wolter-Desfosses M, Janier M, Baccard M, Bezier M, Broissin M, Colin De Verdiere N, Durupt F, Hope Rapp E, Juillard C, Levy A, Moraillon I, Petit A, Regner S, Barthelme D, Tamarin JM, Begon E, Strady C, Gangneux JP, Carpentier O, Mechai F, Kieffer C, Dellestable P, Rebauder S. Travelers With Cutaneous Leishmaniasis Cured Without Systemic Therapy. Clin Infect Dis 2013; 57:370-80. [DOI: 10.1093/cid/cit269] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- G. Morizot
- Unité d'Immunologie Moléculaire des Parasites, Institut Pasteur de Paris
| | | | - O. Mouri
- Service de Parasitologie-Mycologie
| | | | - A. Pérignon
- Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris
| | - F. Foulet
- Service de Parasitologie-Mycologie, Hôpital Henri Mondor, Créteil
| | | | - E. Bourrat
- Service de Dermatologie, Hôpital Saint-Louis, Paris
- Service de Pédiatrie générale, Hôpital Robert Debré, Paris, France
| | - E. Laffitte
- Clinique de Dermatologie, Hôpitaux Universitaires de Genève, Switzerland
| | - I. Alcaraz
- Service de Maladies Infectieuses et Pathologie du voyageur, Hôpital Gustave Dron, Tourcoing
| | - N. Bodak
- Service de Dermatologie, Hôpital Necker, Paris
| | - C. Ravel
- French Reference Centre on Leishmaniasis, Montpellier
| | - M. Vray
- Unité de Recherche et d'Expertise Épidémiologie des Maladies Émergentes, Institut Pasteur de Paris/INSERM, France
| | - M. Grogl
- Walter Reed Army Institute of Research, Silver Spring, Maryland
| | | | - E. Caumes
- Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris
| | - L. Lachaud
- French Reference Centre on Leishmaniasis, Montpellier
| | - P. A. Buffet
- Unité d'Immunologie Moléculaire des Parasites, Institut Pasteur de Paris
- Service de Parasitologie-Mycologie
- UMRs 945 INSERM–Paris 6 University, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Amy de la Bretèque M, Rybojad M, Cordoliani F, Petit A, Juillard C, Flageul B, Bachelez H, Bagot M, Bouaziz JD. Étude rétrospective sur 28 patients évaluant l’efficacité de la corticothérapie générale dans les morphées profondes et superficielles étendues de l’adulte. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Amy de la Bretèque M, Rybojad M, Cordoliani F, Petit A, Juillard C, Flageul B, Bagot M, Bouaziz JD. Relapse of severe forms of adult morphea after oral corticosteroid treatment. J Eur Acad Dermatol Venereol 2012. [DOI: 10.1111/jdv.12039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Sené T, Juillard C, Rybojad M, Cordoliani F, Morel P, Guibal F. Traitement par infliximab de la sarcoïdose cutanée réfractaire : étude rétrospective monocentrique de 9 patients. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Juillard C, Mballa GAE, Nyemb N, Stevens KA, Hyder AA. Patterns of injury and violence in Yaound Cameroon: an analysis of hospital data. Inj Prev 2010. [DOI: 10.1136/ip.2010.029215.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Abstract
BACKGROUND Mortality from road traffic injuries in sub-Saharan Africa is among the highest in the world, yet data from the region are sparse. To date, no multi-site population-based survey on road traffic injuries has been reported from Nigeria, the most populated country in Africa. OBJECTIVE To explore the epidemiology of road traffic injury in Nigeria and provide data on the populations affected and risk factors for road traffic injury. DESIGN Data from a population-based survey using two-stage stratified cluster sampling. SUBJECTS/ SETTING: Road traffic injury status and demographic information were collected on 3082 respondents living in 553 households in seven of Nigeria's 37 states. MAIN OUTCOME MEASURES Incidence rates were estimated with confidence intervals based on a Poisson distribution; Poisson regression analysis was used to calculate relative risks for associated factors. RESULTS The overall road traffic injury rate was 41 per 1000 population (95% CI 34 to 49), and mortality from road traffic injuries was 1.6 per 1000 population (95% CI 0.5 to 3.8). Motorcycle crashes accounted for 54% of all road traffic injuries. The road traffic injury rates found for rural and urban respondents were not significantly different. Increased risk of injury was associated with male gender among those aged 18-44 years, with a relative risk of 2.96 when compared with women in the same age range (95% CI 1.72 to 5.09, p<0.001). CONCLUSIONS The road traffic injury rates found in this survey highlight a neglected public health problem in Nigeria. Simple extrapolations from this survey suggest that over 4 million people may be injured and as many as 200 000 potentially killed as the result of road traffic crashes annually in Nigeria. Appropriate interventions in both the health and transport sectors are needed to address this significant cause of morbidity and mortality in Nigeria.
Collapse
Affiliation(s)
- M Labinjo
- World Health Organization, Abuja, Nigeria
| | | | | | | |
Collapse
|
15
|
Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol 2008; 197:147-51. [PMID: 18555540 DOI: 10.1016/j.jneuroim.2008.04.033] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2008] [Revised: 04/28/2008] [Accepted: 04/29/2008] [Indexed: 11/24/2022]
Abstract
Interferon-beta (IFN-beta) achieves its beneficial effect on multiple sclerosis (MS) via anti-inflammatory properties. In this study, we assessed the expression of the brain-derived neurotrophic factor (BDNF) in peripheral blood mononuclear cells (PBMC) from relapsing-remitting multiple sclerosis (RRMS) patients treated or not with IFN-beta. Intracellular BDNF was measured by Western blot and ELISA and compared with serum BDNF. We found higher levels of BDNF in PBMC of IFN-beta-treated versus non-treated patients, whereas serum levels of BDNF were similar. We hypothesize that the increased intracellular BDNF secondary to IFN-beta is not released in the periphery. This release is probably not tissue specific but in MS patients, BDNF could be specifically delivered by PBMC at the site of re-activation, i.e. within the central nervous system.
Collapse
Affiliation(s)
- P H Lalive
- Department of Neurosciences, Neuroimmunology Laboratory, University Hospital of Geneva, Geneva, Switzerland.
| | | | | | | | | |
Collapse
|
16
|
Bourrat E, Cordoliani F, Juillard C, Saada V, Morel P. Trois maladies graves inaugurées par une glossite. Ann Dermatol Venereol 2008; 135:167-9. [DOI: 10.1016/j.annder.2007.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2007] [Accepted: 05/25/2007] [Indexed: 10/22/2022]
|
17
|
Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, Zamvil SS, Gougeon ML, Chofflon M, Lalive PH. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol 2007; 185:123-9. [PMID: 17306890 DOI: 10.1016/j.jneuroim.2006.12.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2006] [Revised: 12/12/2006] [Accepted: 12/22/2006] [Indexed: 11/23/2022]
Abstract
We investigated whether glatiramer acetate (GA) treatment may affect Th1 differentiation at various T-cell maturation stages. Specifically, we analyzed the effect of in vivo GA treatment on intracellular synthesis of IL-2 and TNF-alpha by naive, memory and effector CD4(+) and CD8(+) T cells by five-colour flow cytometry. Our data indicate that GA treatment downregulates/normalizes an accelerated Th1 differentiation of CD4(+) T cells in RRMS patients at all stages of T-cell maturation. Most notably, we conclude that, by altering naive, unprimed CD4(+) T cells, GA treatment appears to affect T-cell differentiation, at least in part, in an antigen-independent manner.
Collapse
Affiliation(s)
- S Kantengwa
- Department of Neurology, Neuroimmunology Laboratories, University Hospital of Geneva, Micheli-du-Crest 24, 1211 Geneva 14, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Vignon-Pennamen MD, Juillard C, Rybojad M, Wallach D, Daniel MT, Morel P, Verola O, Janin A. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. ACTA ACUST UNITED AC 2006; 142:1170-6. [PMID: 16983004 DOI: 10.1001/archderm.142.9.1170] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND Sweet syndrome is an acute neutrophilic dermatosis that occurs with malignant diseases, mainly myeloid hemopathies, in about 20% of cases. When associated with myelodysplasia, Sweet syndrome may be clinically atypical. It can be histologically unusual. Concomitant infiltration of mature neutrophils and immature myeloid cells has been reported, and its significance is still debated. In few patients, lymphocytic infiltrates are the presenting feature of Sweet syndrome with myelodysplasia. OBSERVATIONS We present 9 male adult patients with chronic Sweet syndrome, all with recurrent eruptions of erythematous and annular plaques that were associated with relapsing polychondritis in 4 of the 9 patients. Results from sequential biopsies showed that infiltrates were initially composed of lymphocytes and that neutrophilic dermal infiltration typical of Sweet syndrome occurred 24 to 96 months later, except in 2 cases. Moreover, atypical mononuclear cells were present on all initial biopsy specimens and strongly reacted to CD68 and myeloperoxidase, indicating a myeloid origin. Myelodysplastic syndrome occurred in all 9 patients, concomitantly with the neutrophilic infiltrate in 4 cases. CONCLUSIONS Lymphocytic infiltrates with a clinical aspect of Sweet syndrome might represent the initial stage of a cutaneous dysgranulopoiesis syndrome and should lead to the research of atypical myeloid cells in skin infiltrate, blood, and bone marrow for the early detection of an associated myelodysplastic syndrome.
Collapse
Affiliation(s)
- Marie-Dominique Vignon-Pennamen
- Department of Dermatology, U728 INSERM, University Paris VII, University Institute of Hematology, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris CEDEX 10, France.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Eguia B, Levy A, Juillard C, Jacobelli S, Morel P, Rybojad M. P29 - DRESS grave induit par le léflunomide, avec réactivation de cytomégalovirus. Ann Dermatol Venereol 2005. [DOI: 10.1016/s0151-9638(05)79758-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Juillard C, Cordoliani F, Guibal F, Abecassis S, Fardet L, Morel P, Rybojad M. P78 - Efficacité des immunoglobulines intraveineuses dans le traitement de la vasculite livédoide : 2 cas. Ann Dermatol Venereol 2005. [DOI: 10.1016/s0151-9638(05)79807-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Fellay B, Chofflon M, Juillard C, Paunier AM, Landis T, Roth S, Gougeon ML. Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis. Immunology 2001; 104:383-91. [PMID: 11899423 PMCID: PMC1783317 DOI: 10.1046/j.1365-2567.2001.01322.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Multiple sclerosis (MS) has been associated with an imbalance in the T helper type 1 (Th1) and Th2 subsets. We investigated, at the single-cell level, the synthesis of pro-inflammatory cytokines by CD4 and CD8 T cells from MS patients. We report the relationship between priming of CD4 and CD8 T cells for interleukin-2 (IL-2), interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) and disease evolution in MS patients, clinically subdivided into relapsing-remitting MS (RRMS) in remission, RRMS in relapse, or chronic progressive MS (CPMS). Moreover, we report the in vivo influence of co-polymer 1 (COP) treatment on the pattern of cytokine producers in RRMS patients. We show that the frequency of CD4 T cells primed for TNF-alpha synthesis increased in all stages of MS, including RRMS remitting, and was normalized to control values in COP-treated patients (43.2 +/- 11.8% in treated patients versus 47 +/- 7.3% in RRMS remitting versus 40.3 +/- 8% in controls). In addition, a significant decrease in the frequency of CD4 T cells primed for IL-2 was found in COP-treated patients as compared to the other groups of patients, reaching values below that of controls (59.1 +/- 9.9% in treated patients versus 70 +/- 11.6% in RRMS remitting versus 67.1 +/- 7.4% in controls). Unexpectedly, COP-treated patients also showed a significantly decreased priming for IFN-gamma at the CD4 T-cell level (9.1 +/- 3.4% in treated patients versus 18.8 +/- 0.6.4% in RRMS remitting versus 15.4 +/- 4.7% in controls), but not at the CD8 T-cell level. This bystander suppression on the inflammatory cells should be considered in the monitoring of MS patients submitted to COP treatment, in order to evaluate better its clinical efficacy.
Collapse
Affiliation(s)
- B Fellay
- Laboratory of Neuroimmunology, Department of Neurology, University Hospital of Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Chofflon M, Roth S, Juillard C, Paunier AM, Juillard P, Degroote D, Grau GE. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis. Eur Cytokine Netw 1997; 8:253-7. [PMID: 9346357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The aim of this study was to develop a test allowing to monitor disease activity in patients with multiple sclerosis (MS). A simple, fast and reliable test was used to assess the cytokine production capacity of blood leucocytes. The whole blood test (WBT) involved in vitro stimulation of a whole blood sample with either the mitogen phytohaemagglutinin (PHA), or specific antigens. We focused our attention on the production of tumor necrosis factor alpha (TNF), because of the possible involvement of this cytokine in MS pathogenesis. Under in vitro stimulation with PHA or MBP, TNF production was found to be significantly higher in patients during the clinical relapses than during remissions. The increment of TNF production correlated with the severity of the relapses, as determined by the modification of Kurtzke EDSS scale. Moreover, each clinical relapse appeared to be preceded by a peak of TNF production. We then retrospectively analysed 21 patients with the relapsing-remitting form of the disease, in whom the WBT was performed every 2-4 weeks, for periods ranging from 16 to 52 months. Seventy-three peaks of TNF production (defined as the doubling or more of the individual baseline value, which was found to be stable for each patient during remissions), and 47 relapses, including 36 objective and 11 subjective, were observed. Forty-seven out of the 73 TNF peaks were followed by or concomitant with a clinical relapse. In 10 out of the 26 cases where no relapse followed the TNF peak, another cause (mainly infections) of increased TNF production was found. Thus, by excluding other causes, the specificity of the WBT, i.e., the probability to develop a relapse when a TNF peak was found to be 74.6% (47/63). The sensitivity of the WBT was 100%, since all the 47 relapses were preceded by a TNF peak. Assessment of TNF production capacity by the WBT may thus be useful in the follow-up of MS patients, particularly for the follow-up of various treatments. Information provided by the WBT may also be useful to orientate the therapeutic decision for an incipient relapse. Earlier treatment is likely to result in an improved prevention of neurological damage.
Collapse
Affiliation(s)
- M Chofflon
- Division of Neurology, Hôpital Cantonal, Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
24
|
Lou J, Chofflon M, Juillard C, Donati Y, Mili N, Siegrist CA, Grau GE. Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity. Neuroreport 1997; 8:629-33. [PMID: 9106736 DOI: 10.1097/00001756-199702100-00010] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The adhesion properties of brain microvascular endothelial cells (MVEC) and leukocytes derived from patients with multiple sclerosis (MS) were investigated. Leukocytes and brain MVEC from MS patients exhibited significantly higher adhesion capacity than the same cells isolated from normal donors. Flow cytometry showed that MS-derived brain MVEC constitutively expressed higher levels of ICAM-1 and contained an increased proportion of MHC class II positive cells than normal brain MVEC. In contrast, no difference was seen for vascular cell adhesion molecule-1 and endothelial cell leukocyte adhesion molecule-1. Circulating leukocytes from MS patients expressed higher levels of LFA-1, a ligand of intercellular adhesion molecule-1 (ICAM-1), than did normal leukocytes. The data presented here suggest that the ICAM-1/LFA-1 interaction may determine cytoadherence of leukocytes to brain MVEC in MS.
Collapse
Affiliation(s)
- J Lou
- Department of Anaesthesiology, Pharmacology, and Surgical Intensive Care, Hôpital Cantonal Universitaire, Centre Médical Universitaire (CMU), University of Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
25
|
Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992; 3:523-31. [PMID: 1296800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
No biological parameter is currently available as a specific marker of multiple sclerosis (MS) activity. The aim of this study was to determine whether an evolution of the neurological disability is associated with a modified profile of cytokine production. Clinical disease activity was quantitated by the Kurtzke's expanded disability status scale (EDSS). Whole blood was stimulated with phytohemagglutinin (PHA) for 2 hours at 37 degrees C and the activated plasma was assayed for Tumor necrosis factor alpha (TNF-alpha) and Interleukin-1 beta (IL-1 beta). Relapsing-remitting MS patients enduring a relapse (RRMS, in relapse) (721 +/- 58 pg/ml, n = 27) and chronic progressive MS (CPMS) patients (516 +/- 33 pg/ml, n = 17) had an higher TNF-alpha production capacity as compared to healthy subjects (143 +/- 25 pg/ml, n = 17), RRMS, stable patients, (123 +/- 11 pg/ml, n = 26) or other neurological diseases (OND) without immunological or inflammatory disease in the peripheral immune compartment (131 +/- 24 pg/ml, n = 14) (t test: p < 0.0001). IL-1 beta production was also significantly higher but to a lesser extent in the same conditions. Concentration of TNF-alpha was also found to be significantly higher in the cerebrospinal fluid (CSF) of CPMS patients (199 +/- 7.8 pg/ml, n = 7, p < 0.0001) but also in RRMS, in relapse (149 +/- 5.7 pg/ml, n = 11, p < 0.05) as compared to RRMS, stable (130 +/- 4.4 pg/ml, n = 7) or OND without inflammatory or immunological disease of the central nervous system (CNS) (142 +/- 6.2 pg/ml, n = 8).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M Chofflon
- Clinic of Neurology, Hôpital Cantonal Universitaire, Geneva, Switzerland
| | | | | | | | | |
Collapse
|
26
|
Bachmann M, Chevallier B, Clément C, Duruz N, Dutoit-Marco ML, Hersch D, Juillard C, Juillerat C, Matthieu-Bourdeau L. [New options concerning the management of the hearing-impaired child]. Rev Med Suisse Romande 1986; 106:425-30. [PMID: 3726380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|